Therapeutic Rest to Delay Admission in Early Labor: A Prospective Study on Morphine Sleep

Sponsor
University of California, San Francisco (Other)
Overall Status
Completed
CT.gov ID
NCT03539562
Collaborator
(none)
82
1
30.1
2.7

Study Details

Study Description

Brief Summary

This will be a prospective study on labor characteristics, and obstetric and neonatal outcomes in women who accept and women who decline morphine as a form of pain management in labor. The study will also investigate patient satisfaction with this form of analgesia. The participants will be those who accept morphine and promethazine and those who decline morphine and promethazine for pain control.

Condition or Disease Intervention/Treatment Phase
  • Drug: Morphine Sulfate and Promethazine

Detailed Description

Objective: Therapeutic rest in labor involves administration of parenteral analgesics in early or prodromal labor to relieve the patient's discomfort and allow for progression of labor while the patient rests. No prospective studies exist which examine the safety and clinical utility of therapeutic rest in early labor, and no published studies examine the potential benefits of therapeutic rest from the perspective of either patient satisfaction or cost-effectiveness. The investigators aim to determine whether therapeutic rest using morphine and promethazine is associated with variations in labor characteristics, or obstetric or neonatal outcomes as well as patient satisfaction with this form of pain management.

Methods: This will be a prospective cohort study. Women who are eligible for therapeutic rest (reactive non-stress test, normal amniotic fluid, in prodromal or early labor as defined by obstetric provider, and plan to discharge home after evaluation) will be recruited for the study. Participants will receive routine obstetric care by providers who are unaware of patient enrollment. A research assistant will then approach all participants in the postpartum period, prior to discharge from the hospital or with a phone call if permitted by the patient, to complete a questionnaire including patient satisfaction items. Chart review will be performed to determine differences in hospital stay and common obstetric and neonatal outcomes to compare these data among women who do and do not choose to receive therapeutic rest. These results will provide insight into a common clinical practice, helping to not only guide management at institutions where therapeutic rest is commonly utilized but also potentially encourage its initiation at hospitals were therapeutic rest is not available.

Study Design

Study Type:
Observational
Actual Enrollment :
82 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Therapeutic Rest to Delay Admission in Early Labor: A Prospective Study on Morphine Sleep
Actual Study Start Date :
Sep 27, 2017
Actual Primary Completion Date :
Apr 1, 2020
Actual Study Completion Date :
Apr 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Accepted Morphine Sulfate

Patients accepted morphine and promethazine as a method for pain management in early or prodromal labor.

Drug: Morphine Sulfate and Promethazine
Morphine sulfate and promethazine
Other Names:
  • Morphine Sleep
  • Declined Morphine Sulfate

    Patients declined morphine and promethazine as a method for pain management in early or prodromal labor.

    Outcome Measures

    Primary Outcome Measures

    1. The proportion of women who were admitted in active labor (6 cm or greater cervical dilation). [0 hours to 2 weeks]

      Admission in active labor

    Secondary Outcome Measures

    1. Time in hours between the start of contractions to being offered therapeutic rest [1-2 weeks after delivery]

      Duration of contractions in hours before presenting for rule out labor

    2. Time in hours between being offered therapeutic rest and admission to labor and delivery [1-2 weeks after delivery]

      Latency period between being offered therapeutic rest and admission

    3. Time in hours between admission to labor and delivery and complete cervical dilation [1-2 weeks after delivery]

      Length of admission

    4. Time in hours between admission to labor and delivery and birth time [1-2 weeks after delivery]

      Length of admission

    5. Time in hours between complete cervical dilation and birth time [1-2 weeks after delivery]

      Length of second stage

    6. Proportion of women who required induction of labor [1-2 weeks after delivery]

      Induction of labor

    7. Proportion of women who required augmentation of labor [1-2 weeks after delivery]

      Augmentation of labor

    8. Proportion of women who received an epidural [1-2 weeks after delivery]

      Epidural use

    9. Type of delivery [1-2 weeks after delivery]

      Mode of delivery

    10. Proportion of women diagnosed with chorioamnionitis [1-2 weeks after delivery]

      Presence of maternal infection

    11. APGAR scores of neonate [1-2 weeks after birth]

      Neonatal clinical assessment

    12. Umbilical cord gas values [1-2 weeks after birth]

      Neonatal laboratory assessment

    13. Proportion of newborns admitted to Intensive Care Nursery [1-2 weeks after birth]

      Neonatal Intensive Care Unit admission

    14. Neonatal Intensive Care Unit length of stay in days [1-2 weeks after birth]

      Length of stay in the Intensive Care Nursery

    15. Proportion of women with meconium present during labor [1-2 weeks after delivery]

      Presence of meconium

    16. Patient responses (yes or no) to a 4-question survey conducted after delivery to determine satisfaction with morphine and promethazine as a form of therapeutic rest. [1-4 weeks after delivery]

      Patient satisfaction assessment

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 55 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Singleton pregnancies between 37w0d and 41w6d gestation

    • Presentation to triage for rule out labor as primary indication and found to be in early labor

    • Offered therapeutic rest by obstetric provider with plan to discharge home after evaluation

    Exclusion Criteria:
    • Allergy to morphine sulfate or promethazine

    • Being without an attendant to safely transport the patient home

    • Present to triage for other indication (decreased fetal-movement, premature rupture of membranes, hypertension, etc.)

    • Multiple gestation

    • Known fetal anomaly

    • Placenta previa, active maternal Herpes Simplex Virus disease, or any other contraindication to vaginal delivery

    • Recommendation for direct admission to L&D for maternal or fetal indication.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 UCSF Medical Center at Mission Bay San Francisco California United States 94158

    Sponsors and Collaborators

    • University of California, San Francisco

    Investigators

    • Principal Investigator: Stephanie L Gaw, MD, PhD, University of California, San Francisco

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    University of California, San Francisco
    ClinicalTrials.gov Identifier:
    NCT03539562
    Other Study ID Numbers:
    • 17-21855
    First Posted:
    May 29, 2018
    Last Update Posted:
    Jul 29, 2020
    Last Verified:
    Jul 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 29, 2020